Loading...
Loading...
SAVA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 26.5M |
| Operating I/L | -26.9M |
| Other Income/Expense | 2.2M |
| Interest Income | 2.1M |
| Pretax | -24.3M |
| Income Tax Expense | -2.6M |
| Net Income/Loss | -21.6M |
Cassava Sciences, Inc. is a clinical stage biotechnology company focused on developing drugs for neurodegenerative diseases. Its lead therapeutic product candidate, simufilam, is a small molecule drug that has completed Phase 2b clinical trial. The company also has an investigational diagnostic product candidate, SavaDx, which is a blood-based biomarker/diagnostic designed to detect Alzheimer's disease.
